article thumbnail

FDA approves first liquid biopsy test that uses advanced gene sequencing

Bio Pharma Dive

The test, developed by Guardant Health, combines next-generation sequencing with a cancer blood test

article thumbnail

PacBio Secures $900 Million Investment to Support Gene Sequencing

BioSpace

will make an investment of $900 million into the company to support its gene sequencing research Shares of Pacific Biosciences soared more than 21% in premarket trading after it was announced SB Management, a subsidiary of SoftBank Group Corp.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ring 20: Could the rare disease get left behind by next-generation gene sequencing?

Pharma Phorum

Ring Chromosome 20 Syndrome, or (R)20, is an ultra-rare form of epilepsy with a devastating impact – yet despite huge leaps forward in gene sequencing in recent years, diagnoses are going down instead of up.

article thumbnail

Next Generation Sequencing (NGS) Library Preparation Kits Market: Current Scenario and Future Potential

Roots Analysis

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advantages of Next Generation Sequencing.

article thumbnail

Next Generation Sequencing (NGS) Library Preparation Kits: Revolutionizing the Field of Genetic Sciences

Roots Analysis

Over the past few years, several companies have started offering a diverse range of genome sequencing products and services using various second and third generation sequencing technologies. Next Generation Sequencing (NGS) Library Preparation Kits.

article thumbnail

First of its kind SARS-CoV-2 detection by partial N gene sequencing now publicly available at CLIA Certified Milford Connecticut laboratory

BioTech 365

First of its kind SARS-CoV-2 detection by partial N gene sequencing now publicly available at CLIA Certified Milford Connecticut laboratory First of its kind SARS-CoV-2 detection by partial N gene sequencing now publicly available at CLIA Certified Milford Connecticut laboratory … Continue reading → Business Wire

article thumbnail

Companion Diagnostics Markets, 2025 – Immunohistochemistry, Polymerase Chain Reaction, In-situ Hybridization, Real-time PCR, Gene Sequencing – ResearchAndMarkets.com

BioTech 365

Companion Diagnostics Markets, 2025 – Immunohistochemistry, Polymerase Chain Reaction, In-situ Hybridization, Real-time PCR, Gene Sequencing – ResearchAndMarkets.com Companion Diagnostics Markets, 2025 – Immunohistochemistry, Polymerase Chain Reaction, In-situ Hybridization, Real-time PCR, Gene Sequencing – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Companion Diagnostics Market: Global … Continue reading → Business Wire

article thumbnail

#news #biotech Research team develops software that cuts time, cost from gene sequencing

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Research team develops software that cuts time, cost from gene sequencing.A team of Johns Hopkins University researchers has developed a new software that could revolutionize how DNA … Continue reading → #news

DNA 40
article thumbnail

Oxford Nanopore makes stellar debut on UK stock market

Pharma Phorum

Shares in DNA sequencing specialist Oxford Nanopore rocketed after the company made its debut on the London Stock Exchange yesterday, rising nearly 50% to propel its valuation up towards the £5 billion ($6.7

article thumbnail

How COVID-19 is Still Changing the Biopharma Industry, Now and in the Future

BioSpace

The development of COVID-19 vaccines, which took only months from the initial gene sequencing to the time shots were in arms, was the biggest story of 2020 alongside the pandemic itself

article thumbnail

Study suggests that most of our evolutionary trees could be wrong

Scienmag

New research led by scientists at the Milner Centre for Evolution at the University of Bath suggests that determining evolutionary trees of organisms by comparing anatomy rather than gene sequences is misleading. The study, published in Communications Biology, shows that we often need to overturn centuries of scholarly work that classified living things according to […]. Latest News evolutionary study suggests trees wrong

article thumbnail

Hopkins-led research team takes gene mutation detection in blood to the next level

Scienmag

Credit: Elizabeth Cooke Next-generation gene sequencing (NGS) technologies –in which millions of DNA molecules are simultaneously but individually analyzed– theoretically provides researchers and clinicians the ability to noninvasively identify mutations in the blood stream.

article thumbnail

Innovation massively expands view into workings of single cells

Scienmag

New method yields 10 times more data, reduces gene sequencing costs by one third Researchers have devised a way to multiply by more than ten-fold the accessible details of gene activity in individual cells. It’s a big leap in the effort to understand cancer development, brain function, immunity and other biological processes driven by the […].

article thumbnail

#news #biotech Algorithm maps gene expression in space

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Algorithm maps gene expression in space.As we accumulate more and more gene-sequencing information, cell-type databases are growing in both size and complexity. There is a need to … Continue reading → #news

article thumbnail

GenapSys Names Jason Myers CEO

BioTech 365

GenapSys), the company behind the world’s first highly accurate, affordable, and accessible gene sequencer, today announced it has named Jason Myers as its Chief Executive … Continue reading → Business WireGenapSys Names Jason Myers CEO GenapSys Names Jason Myers CEO REDWOOD CITY, Calif.–(BUSINESS –(BUSINESS WIRE)–GenapSys Inc.

article thumbnail

Boost for mRNA as Moderna to acquire OriCiro for $85 million

Pharma Phorum

The data was from their phase 2b trial of a personalised vaccine consisting of 34 mRNAs, each targeting mutations – identified by gene sequencing – thought to be driving a patient’s cancer. Biotech Moderna, Inc. and OriCiro Genomics K.K.

article thumbnail

Merck and Moderna’s mRNA cancer vaccine aces its first efficacy trial

Pharma Phorum

The two partners have revealed the first clinical data from a phase 2b trial of a personalised vaccine consisting of 34 mRNAs, each targeting mutations – identified by gene sequencing – that are thought to be driving a patient’s cancer.

article thumbnail

New CRISPR-Based Tool Called PASTE Gene Editing Inserts Large DNA Sequences at Desired Sites

XTalks

Expanding upon the CRISPR-Cas9 gene editing system, researchers at MIT have designed a new technique called PASTE gene editing that can cut out defective genes and replace them with new genes in a safer and more efficient way. How does the Gene Editing Tool PASTE Work?

article thumbnail

Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis

Pharma Phorum

Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Precision BioSciences, focused on a therapy for sickle cell disease (SCD). News R&D beta thalassaemia gene editing Haematology Novartis partnering Precision BioSciences sickle cell disease

article thumbnail

Takeda grows in gene therapies again with $2bn Code Bio deal

Pharma Phorum

Takeda has forged another alliance as it continues a push into gene therapy, agreeing a deal worth up to $2 billion with Code Biotherapeutics for opt-in rights to four candidates for rare diseases. The post Takeda grows in gene therapies again with $2bn Code Bio deal appeared first on.

article thumbnail

Scenic Bio raises $31m for genetic modifier platform

Pharma Phorum

Scenic’s platform technology Cell-Seq is used to seek out genetic modifiers, defined as gene sequences that counteract the effect of another disease-associated gene.

article thumbnail

Merck gets on board with Moderna cancer vaccine in $250m deal

Pharma Phorum

The neoantigens are selected based on gene sequencing of either a tumour biopsy or a blood sample, with an individual vaccine tailored to the patient manufactured and administered in a matter of weeks.

article thumbnail

SparingVision raises €75m for eye disease gene therapies

Pharma Phorum

SparingVision has raised €75 million in second-round funding that will be used to fund clinical trials of gene therapies for ocular diseases retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD).

article thumbnail

Sensyne, Oxford University deploy AI to find asthma targets

Pharma Phorum

The three-year project – led by respiratory medicine expert Dr Timothy Hinks from the Oxford University Respiratory Medicine Unit – will use whole-genome sequencing of around 500 patients with severe asthma, comparing their gene sequences with control subjects who don’t have asthma.

article thumbnail

The Nobel Prize in Physiology or Medicine 2022

The Pharma Data

Through his pioneering exploration, Svante Pääbo fulfilled commodity putatively insolvable sequencing the genome of the barbarous, an defunct relation of present- day humans. Importantly, Pääbo also set up that gene transfer had passed from these now defunct hominins to Homo sapiens following the migration out of Africa around,000 times agone. The exploration platoon exploited new specialized developments, which made sequencing of DNA largely effective.

Genome 63
article thumbnail

Illumina debuts its multi-gene test for cancer in Europe

Pharma Phorum

Gene sequencing specialist Illumina has started rolling out a new test that looks for a battery of tumour-associated genes from a single tissue sample, and could be used to help guide treatment for a broad range of cancers.

article thumbnail

Gene therapy specialist bluebird exits “untenable” European market

Pharma Phorum

Europe market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene therapies that bluebird bio has decided to quit the market altogether, according to Andrew Obenshain, president of its severe genetic diseases unit.

article thumbnail

UK cancer mutation testing firm Biofidelity raises $12m

Pharma Phorum

Cambridge, UK-based Biofidelity has raised $12 million in first-round funding for its cancer diagnosis platform, which can detect mutations quicker than current approaches like gene sequencing.

DNA 56
article thumbnail

Medicago, GSK’s plant-made COVID jab clears phase 2

Pharma Phorum

The advantage of plant-based production is that it is quick – Medicago says it produced the main ingredient for its vaccine just 20 days after the gene sequence of SARS-CoV-2 was published – and is easily scalable simply by cultivating additional plants.

article thumbnail

Vertex eyes controllable genetic drugs with $1.3bn Obsidian alliance

Pharma Phorum

Vertex Pharma has ramped up its involvement in gene-editing medicines for the second time in a week, paying Obsidian Therapeutics $75 million upfront to access its technology platform. . News R&D CRISPR Therapeutics CRISPR/Cas9 gene editing Obsidian Therapeutics partnering Vertex Pharma

article thumbnail

Zynteglo halt re-ignites viral vector safety concerns; analysts

Pharma Phorum

Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors used to deliver gene therapies resurface. .

article thumbnail

West Africa prepares for Ebola vaccination program

Pharma Phorum

Moeti added there was a need to build sequencing capacity to detect different variants. Since 2020 there has been a 50% increase in sequences produced in African countries. Amidst the COVID-19 pandemic, West Africa is facing a new outbreak of Ebola.

article thumbnail

Fulgent Genetics Extends Partnership with New York City Test and Trace for COVID-19 Testing, Awarded Contract for 2021 School Year

The Pharma Data

Combining next generation sequencing (“NGS”) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. TEMPLE CITY, Calif.,